



1000 Harrington Boulevard
Mount Clemens, Michigan 48043
Telephone (313) 466-8000

MOUNT CLEMENS GENERAL HOSPITAL

November 21, 1985

United States Nuclear Regulatory Commission
Region II, Office of Materials Licensing
799 Roosevelt Road
Glen Ellyn, Illinois 60137

ATTN: Bruce Mallett, Ph.D.

RE: Request for amendment to NCR License No. 21-04080-01.

We hereby request the following changes to our NRC License:

The deletion of W. Dale Rankin, D.O. as an authorized user of our License for 10 CFR 35.100 Schedule A groups I, II, and III; I-131 as iodide for treatment of hyperthyroidism; P-32 as soluble phosphate for treatment of polycythmia vera, leukemia, and bone metastasis; Xe-133; and in vitro studies. Dr. Shapiro is currently authorized to use radioactive material with NRC License No. 21-04078-01, Saginaw Osteopathic Hospital. NRC Supplement A & B are included.

Thank you for your help and attention regarding this matter. Enclosed is the \$120.00 fee for the License amendment per 10 CFR 170.31 7.C.

Sincerely,

Charles H. Warren

Administrator
Mt. Clemens General Hospital

8602190495 851213
REG3 LIC30
22-04080-01 PDR

Applicant Dec. 3A III
Check No. 40527
Amount/Fee Category \$120 (7C)
Type of Fee AMD
Date Check Rec'd 12/2/85
Received By AP

RECEIVED
NOV 27 1985
REGION III

U.S. NRC
LIC. FEE MGMT. BRANCH

RECEIVED
85 DEC -2 AM 5:57

NOV 27 1985

TRAINING AND EXPERIENCE
AUTHORIZED USER OR RADIATION SAFETY OFFICER

1. NAME OF AUTHORIZED USER OR RADIATION SAFETY OFFICER Eli Edward Shapiro, D.O.		2. STATE OR TERRITORY IN WHICH LICENSED TO PRACTICE MEDICINE Michigan		
3. CERTIFICATION				
SPECIALTY BOARD A	CATEGORY B	MONTH AND YEAR CERTIFIED C		
American Osteopathic Board of Radiology	Eligible			
4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES				
FIELD OF TRAINING A	LOCATION AND DATE(S) OF TRAINING B	TYPE AND LENGTH OF TRAINING		
		LECTURE/ LABORATORY COURSES (Hours) C	SUPERVISED LABORATORY EXPERIENCE (Hours) D	
a. RADIATION PHYSICS AND INSTRUMENTATION	Atlantic City, 5/82 Chicago, Ill., 4/84 Beaumont Hosp., Royal Oak MI, 4-6/83	20 25 55		
b. RADIATION PROTECTION	Cleveland (Paul Early) 7/84 Beaumont Hosp, MI 5/83	30 7		
c. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY	Beaumont Hosp, MI 4-6/83	15	10	
d. RADIATION BIOLOGY	Atlantic City, 5/82 Beaumont Hosp., 4-6/83 Cicago, Ill, 4/84	12 16 7		
e. RADIOPHARMACEUTICAL CHEMISTRY	Beaumont Hosp, Royal Oak MI 4-6/83	17	15	
5. EXPERIENCE WITH RADIATION. (Actual use of Radioisotopes or Equivalent Experience)				
ISOTOPE	MAXIMUM AMOUNT	WHERE EXPERIENCE WAS GAINED	DURATION OF EXPERIENCE	TYPE OF USE
M-99	in generators	Beaumont Hosp. Royal Oak, MI	4/83 - 6/83	generators
Tc-99m	30 mCi			diagnostic
Xe-133	10 mCi			diagnostic
Se-75	250 microCi			diagnostic
In-111	200 microCi			diagnosttic
I-131	10 mCi			therapeutic
P-32	4.5 mCi			therapeutic

PRECEPTOR STATEMENT

Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.

1. APPLICANT PHYSICIAN'S NAME AND ADDRESS

FULL NAME

ELI EDWARD SHAPIRO, D.O.

STREET ADDRESS

902 Sherwood Court

CITY

Rochester

STATE

MI

ZIP CODE

48063

KEY TO COLUMN C

PERSONAL PARTICIPATION SHOULD CONSIST OF:

1-Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage.

2-Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data.

3-Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN

ISOTOPE	CONDITIONS DIAGNOSED OR TREATED	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION	COMMENTS
A	B	C	D
I-131 or I-125	DIAGNOSIS OF THYROID FUNCTION	23	Use In-111 DTPA
	DETERMINATION OF BLOOD AND BLOOD PLASMA VOLUME	0	
	LIVER FUNCTION STUDIES	0	
	FAT ABSORPTION STUDIES	0	
	KIDNEY FUNCTION STUDIES	0	
	IN VITRO STUDIES	14,567	
OTHER		0	
I-125	DETECTION OF THROMBOSIS	1	
I-131	THYROID IMAGING	5	
P-32	EYE TUMOR LOCALIZATION	1	
Se-75	PANCREAS IMAGING	2	
Yb-169	CISTERNOGRAPHY	2	
Xe-133	BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES	81	
OTHER		See attached	
Tc-99m	BRAIN IMAGING & flow	191	
	CARDIAC IMAGING	20	
	THYROID IMAGING	173	
	SALIVARY GLAND IMAGING	1	
	BLOOD POOL IMAGING	270	
	PLACENTA LOCALIZATION	0	
	LIVER AND SPLEEN IMAGING	305	
	LUNG IMAGING	83	
	BONE IMAGING	601	
OTHER		See attached	


PRECEPTOR STATEMENT (Continued)

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
P-32 (Soluble)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES	3	
P-32 (Colloidal)	INTRACAVITARY TREATMENT	0	
I-131	TREATMENT OF THYROID CARCINOMA	0	
	TREATMENT OF HYPERTHYROIDISM	10	
Au-198	INTRACAVITARY TREATMENT	0	
Co-60 or Cs-137	INTERSTITIAL TREATMENT	0	
	INTRACAVITARY TREATMENT	0	
I-125 or Ir-192	INTERSTITIAL TREATMENT	0	
Co-60 or Cs-137	TELETHERAPY TREATMENT	0	
Sr-90	TREATMENT OF EYE DISEASE	0	
	RADIOPHARMACEUTICAL PREPARATION		
Mo-99/ Tc-99m	GENERATOR	Many	
Sn-113/ In-113m	GENERATOR	0	
Tc-99m	REAGENT KITS	Many	
Other			

3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING

April 1, 1983 - June 30, 1983 500 Hours

4. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:		6. PRECEPTOR'S SIGNATURE 	
a. NAME OF SUPERVISOR Howard J. Dworkin, M.D.		7. PRECEPTOR'S NAME (Please type or print) Howard J. Dworkin, M.D.	
b. NAME OF INSTITUTION William Beaumont Hospital			
c. MAILING ADDRESS 3601 West 13 Mile Road			
d. CITY Royal Oak		8. DATE July 5, 1983	
5. MATERIALS LICENSE NUMBER(S) 21-01333-01			

Other studies using Tc-99M

Cystogram	7
Biliary tract scan	102
Renal scan & blood flow	67
Gastro-esophageal reflux	20
Meckel's diverticulum scan	6
Fibrinoben scan	1

Studies using other isotopes

111-In Cisternography	2
67-Ga Scan for abcess	20
57-Co Schilling B-12 test	27
51-Cr Plasma volume	10
201-Tl Cardiac study	402

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number

21-04078-01

Docket or Reference number

030-02039

Amendment No. 38

Saginaw Osteopathic Hospital
515 North Michigan Avenue
Saginaw, MI 48602

In accordance with letter dated April 1, 1985, License Number 21-04078-01 is amended as follows:

Condition 12. is amended to read:

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

M. S. Grillo, D.O.

Groups I, II and III

Xenon-133

In vitro studies

Harvey Minkin, D.O.

Groups I, II and III

Xenon-133

Iodine-131 for treatment of
hyperthyroidism and cardiac
dysfunction

In vitro studies

Suryara Kurumety, M.D.

Groups I, II and III

Xenon-133

Iodine-131 for treatment of
hyperthyroidism, cardiac
dysfunction or thyroid carcinoma

Allan J. Paris, Jr., D.O.

Groups I, II and III

Xenon-133

In vitro studies

Eli Edward Shapiro, D.O.

Groups I, II and III

Iodine-131 for treatment of
hyperthyroidism

Mei-ku Huang, M.D.

Groups I, II and III

Xenon-133

In vitro studies

For the U.S. Nuclear Regulatory Commission

Date

JUN 4 1985

By

B. J. Helt

Materials Licensing Section, Region III

~~8506240107~~

CONTROL NO. 80224